Summary & Overview

Percutaneous Coronary Atherectomy with Intraluminal Device with MCC: Inpatient Reimbursement Overview

DRG 359 encompasses percutaneous coronary atherectomy with intraluminal device placement in patients with a Major Complication or Comorbidity and involves complex percutaneous coronary interventions that increase resource needs. Proper assignment of this Diagnosis-Related Group impacts inpatient reimbursement from Medicare because the Major Complication or Comorbidity status elevates payment relative to lower-severity groups.

Percutaneous Coronary Atherectomy with Intraluminal Device with MCCDRG Percutaneous Coronary Atherectomy with Intraluminal Device with MCCDRG 359Diagnosis-Related GroupInpatient ReimbursementMedicareCardiologyInterventional CardiologyPercutaneous Coronary Intervention

DRG 359 Overview

DRG 359 covers hospital admissions for percutaneous coronary atherectomy with placement of an intraluminal device in patients who have a Major Complication or Comorbidity. These are high-acuity percutaneous coronary interventions performed for complex coronary lesions that often require specialized equipment and longer procedure times. This Diagnosis-Related Group matters for Medicare payment because cases with a Major Complication or Comorbidity typically generate higher resource use and result in higher inpatient reimbursement relative to lower-severity groupings. Accurate clinical documentation of the Major Complication or Comorbidity drives appropriate Diagnosis-Related Group assignment and payment.

Clinical Trials

Trials comparing different intraluminal device strategies or adjunctive technologies used during percutaneous coronary atherectomy procedures in patients with complex coronary lesions (for example heavily calcified or in-stent restenosis): these studies enroll adults undergoing percutaneous coronary atherectomy with a focus on procedural endpoints such as procedural success, device deliverability, acute lumen gain, and peri-procedural complications. They are relevant because device choice and technique directly affect index hospitalization resource use, complication rates, and short-term readmissions that drive DRG costs and provider quality metrics.
Comparative effectiveness studies of atherectomy-based revascularization versus alternative percutaneous strategies (such as high-pressure ballooning, specialty balloons, or rotational/laser atherectomy without intraluminal adjuncts) in high-risk cohorts including elderly patients, those with multivessel disease, or prior coronary stents: these studies evaluate medium-term outcomes like target lesion revascularization, myocardial infarction, and major adverse cardiovascular events over months to a year. Payers and hospitals benefit from evidence on relative durability and downstream utilization because it informs expected longer-term costs, need for repeat procedures, and case mix considerations for DRG budgeting.
Post-discharge outcomes and health services research examining readmission drivers, functional status, quality of life, and cost-effectiveness after percutaneous coronary atherectomy with intraluminal devices in patients with significant comorbidities (such as chronic kidney disease, diabetes, or heart failure): these observational cohorts or pragmatic trials assess patient-centered outcomes, adherence to guideline-directed medical therapy, and patterns of post-acute care. This area is important to providers and payers to identify interventions that reduce avoidable readmissions, optimize discharge dispositions, and improve overall value of care for patients classified under this DRG.

Related Codes

312-SYNCOPE-AND-COLLAPSE

Syncope and Collapse: Inpatient Reimbursement Overview

240-AMPUTATION-FOR-CIRCULATORY-SYSTEM-DISORDERS-EXCEPT-UPPER-LIMB-AND-TOE-WITH-CC

Amputation for Circulatory System Disorders Except Upper Limb and Toe with CC: Inpatient Reimbursement Overview

272-OTHER-MAJOR-CARDIOVASCULAR-PROCEDURES-WITHOUT-CC-MCC

Other Major Cardiovascular Procedures without CC/MCC: Inpatient Reimbursement Overview

220-CARDIAC-VALVE-AND-OTHER-MAJOR-CARDIOTHORACIC-PROCEDURES-WITHOUT-CARDIAC-CATHETERIZATION-WITH-CC

Cardiac Valve and Other Major Cardiothoracic Procedures without Cardiac Catheterization with CC: Inpatient Reimbursement Overview

236-CORONARY-BYPASS-WITHOUT-CARDIAC-CATHETERIZATION-WITHOUT-MCC

Coronary Bypass without Cardiac Catheterization without MCC: Inpatient Reimbursement Overview

282-ACUTE-MYOCARDIAL-INFARCTION-DISCHARGED-ALIVE-WITHOUT-CC-MCC

Acute Myocardial Infarction: Inpatient Reimbursement Overview

271-OTHER-MAJOR-CARDIOVASCULAR-PROCEDURES-WITH-CC

Other Major Cardiovascular Procedures with CC: Inpatient Reimbursement Overview

284-ACUTE-MYOCARDIAL-INFARCTION-EXPIRED-WITH-CC

Acute Myocardial Infarction, Expired with CC: Inpatient Reimbursement Overview

239-AMPUTATION-FOR-CIRCULATORY-SYSTEM-DISORDERS-EXCEPT-UPPER-LIMB-AND-TOE-WITH-MCC

Amputation for Circulatory System Disorders Except Upper Limb and Toe with MCC: Inpatient Reimbursement Overview

321-PERCUTANEOUS-CARDIOVASCULAR-PROCEDURES-WITH-INTRALUMINAL-DEVICE-WITH-MCC-OR-4-ARTERIES-INTRALUMINAL-DEVICES

Percutaneous Cardiovascular Procedures with Intraluminal Device with MCC or 4+ Arteries/Intraluminal Devices: Inpatient Reimbursement Overview

Showing 1–10 of 100

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.